This article was downloaded by: [Laurentian University] On: 11 October 2014, At: 19:40 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides and Nucleotides

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/lncn19

Synthesis and Antiviral Activity of L-2'-Deoxy-2'-up-fluoro-4'-thionucleosides

Lak Shin Jeong $^{\rm a}$, Hyung Ryong Moon $^{\rm a}$, Su Jeong Yoo $^{\rm a}$, Sun Nan Lee $^{\rm a}$, Hee-Doo Kim $^{\rm b}$ & Moon Woo Chun $^{\rm c}$

 $^{\rm a}$ College of Pharmacy, Ewha Womans University , Seoul, 120-750, Korea

^b College of Pharmacy, Sookmyung Women's University, Seoul, 140-742, Korea

 $^{\rm c}$ College of Pharmacy, Seoul National University , Seoul, 151-742, Korea

Published online: 04 Oct 2006.

To cite this article: Lak Shin Jeong , Hyung Ryong Moon , Su Jeong Yoo , Sun Nan Lee , Hee-Doo Kim & Moon Woo Chun (1999) Synthesis and Antiviral Activity of L-2'-Deoxy-2'-up-fluoro-4'-thionucleosides, Nucleosides and Nucleotides, 18:4-5, 571-572, DOI: <u>10.1080/15257779908041497</u>

To link to this article: <u>http://dx.doi.org/10.1080/15257779908041497</u>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &

Conditions of access and use can be found at <u>http://www.tandfonline.com/page/terms-and-conditions</u>

SYNTHESIS AND ANTIVIRAL ACTIVITY OF L-2'-DEOXY-2'-UP-FLUORO-4'-THIONUCLEOSIDES

Lak Shin Jeong,^{1*} Hyung Ryong Moon,¹ Su Jeong Yoo,¹ Sun Nan Lee,¹ Hee-Doo Kim² and Moon Woo Chun³

¹College of Pharmacy, Ewha Womans University, Seoul 120-750, Korea, ²College of Pharmacy, Sookmyung Women's University, Seoul 140-742, Korea and ³College of Pharmacy, Seoul National University, Seoul 151-742, Korea

Abstract: L-2'-Deoxy-2'-up-fluoro-4'-thionucleosides were efficiently synthesized from D-xylose via L-4-thioarabitol derivative as a key intermediate and evaluated for antiviral activities against HIV-1, HSV-1,2 and HBV.

Since the discovery of (-)-L- β -1,3-oxathiolanyl cytosine (3TC, Lamivudine)¹ as potent antiviral agent, a number of L-nucleosides have been synthesized and evaluated for antiviral activity. Among these compounds, 2'-deoxy-2'-fluoro-5-methyl- β -L-arabinofuranosyluracil (L-FMAU) has been reported to exhibit potent anti-hepatitis B virus (HBV) and anti-Epstein-Barr virus (EBV) activities with a favorable toxicity profile.² In an effort to discover analogues to L-FMAU based on a "bioisosteric replacement rationale", we synthesized the 4'-thio congener (L-SFMAU) of L-FMAU and compared its antiviral activity with the parent L-FMAU.³ We also carried out structure-activity relationship study of L-2'-deoxy-2'-up-fluoro-4'-thionucleosides in order to search for new antiviral agents.



571

The key intermediate 2 was synthesized from 1,2-isopropylidene-D-xylose (1) by the efficient procedure developed by our laboratory.⁴ Reaction of 2 with DAST followed by treatment with $Hg(OAc)_2$ did not give the 2-fluoro-4-thiosugar, but yielded a rearranged product 3 by the participation of the anomeric thiobenzyl group. In order to prevent participation from the anomeric center, the thiobenzyl group was converted to an acetate to give 4. However, treatment of 4 with DAST did not give the rearranged product, but gave the ring-contracted product 5 (Scheme 1).



To prevent the rearrangement or ring contraction, the substituent at the anomeric center was removed as shown in Scheme 2. Treatment of **6** with DAST gave the 2-fluoro-4-thiosugar **7** with retention of configuration. Compound **7** was converted to the acetate **8** by treating with mCPBA followed by refluxing with acetic anhydride. Condensation of **8** with silylated pyrimidine and purine bases gave the protected nucleosides **9** which were treated with boron tribromide to yield the final nucleosides $10\alpha-15\alpha$ and $10\beta-15\beta$, respectively. The final nucleosides were assayed against HIV-1, HSV-1, HSV-2, and HBV. The thymine analogue 10β only exhibited moderate activity against both HSV-1 and HSV-2 and all synthesized compounds were found to be inactive against HIV-1.

Acknowledgment

This research was supported by the grant from the STEPI (97-N6-01-01-A-18).

References

- Beach, J. W.; Jeong, L. S.; Alves, A. J.; Pohl, D.; Kim, H. O.; Chang, C.-N.; Doong, S.-L.; Schinazi, R. F.; Cheng, Y.-C.; Chu, C. K. J. Org. Chem. 1992, 57, 2217 and references cited therein.
- Ma, T.; Pai, S. B.; Zhu, Y. L.; Lin, J. S.; Shanmuganathan, K.; Du, J. F.; Wang, C. W.; Kim, H.; Newton, M. G.; Cheng, Y.-C.; Chu, C. K. J. Med. Chem. 1996, 39, 2835.
- Jeong, L. S.; Moon, H. R.; Yoo, S. J.; Lee, S. N.; Chun, M. W.; Lim, Y.-H. Tetrahedron Lett. 1998, 39, 5201.
- Jeong, L. S.; Moon, H. R.; Choi, Y. J.; Chun, M. W.; Kim, H. O. J. Org. Chem. 1998, 63, 4821.